Gain Therapeutics, Inc. (GANX)
NASDAQ: GANX · Real-Time Price · USD
1.850
-0.100 (-5.13%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Gain Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 78 | 124 | 57 | 49 | 37 | 65 | |
| Market Cap Growth | 67.11% | 116.16% | 16.03% | 32.75% | -42.34% | - | |
| Enterprise Value | 58 | 116 | 46 | 38 | 13 | 25 | |
| Last Close Price | 1.85 | 3.22 | 2.16 | 3.27 | 3.13 | 5.43 | |
| PS Ratio | - | - | - | 894.85 | 280.42 | 481.65 | |
| PB Ratio | 4.19 | 6.67 | 7.81 | 3.93 | 1.97 | 1.85 | |
| P/TBV Ratio | 4.23 | 6.71 | 7.95 | 3.99 | 1.99 | 1.86 | |
| EV/Sales Ratio | - | - | - | 691.99 | 96.63 | 186.53 | |
| Debt / Equity Ratio | 0.04 | 0.04 | 0.09 | 0.08 | 0.07 | 0.05 | |
| Net Debt / Equity Ratio | -1.08 | -1.08 | -1.33 | -1.25 | -1.10 | -1.01 | |
| Net Debt / EBITDA Ratio | 1.08 | 1.08 | 0.48 | 0.71 | 1.17 | 2.55 | |
| Net Debt / FCF Ratio | 1.09 | 1.09 | 0.52 | 0.84 | 1.41 | 2.83 | |
| Asset Turnover | - | - | - | 0.00 | 0.00 | 0.01 | |
| Quick Ratio | 6.46 | 6.46 | 2.85 | 3.44 | 4.93 | 14.53 | |
| Current Ratio | 6.63 | 6.63 | 2.97 | 3.59 | 5.11 | 14.78 | |
| Return on Equity (ROE) | -155.66% | -155.66% | -204.95% | -141.57% | -65.52% | -67.73% | |
| Return on Assets (ROA) | -67.01% | -67.01% | -82.80% | -65.14% | -35.24% | -35.60% | |
| Return on Capital Employed (ROCE) | -96.20% | -96.20% | -247.90% | -162.90% | -89.10% | -38.00% | |
| Earnings Yield | -25.80% | -16.28% | -35.63% | -45.10% | -47.29% | -21.53% | |
| FCF Yield | -23.63% | -14.91% | -32.98% | -38.24% | -39.82% | -19.32% | |
| Buyback Yield / Dilution | -44.08% | -44.08% | -75.86% | -9.49% | -16.90% | -279.11% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.